Castle Biosciences (CSTL) Preferred Stock Liabilities (2018 - 2019)
Castle Biosciences (CSTL) posted Preferred Stock Liabilities of $45.1 million for Q2 2019, little changed sequentially from $45.1 million in Q1 2019, and up 0.51% YoY from $44.9 million in Q2 2018.
Castle Biosciences (CSTL) Preferred Stock Liabilities (2018 - 2019) Analysis & Trends
Castle Biosciences has reported Preferred Stock Liabilities for 2 years, with the latest figure at $45.1 million in Q2 2019.
- Quarterly Preferred Stock Liabilities rose 0.51% year-over-year to $45.1 million in Q2 2019, while the trailing twelve-month figure through Jun 2019 was $45.1 million (up 0.51% YoY) and the FY2018 annual result came in at $45.0 million, changed N/A from the prior year.
- Preferred Stock Liabilities was little changed at $45.1 million in Q2 2019 per CSTL's latest filing, from $45.1 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $45.1 million in Q2 2019 and troughed at $44.9 million in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 213.44 Bn | 209.37 Bn | 8.34 Bn | - |
| 2 | Danaher | 139.95 Bn | 135.60 Bn | 3.61 Bn | - |
| 3 | Idexx Laboratories | 46.16 Bn | 45.96 Bn | 779.09 Mn | - |
| 4 | Agilent Technologies | 39.67 Bn | 37.87 Bn | 990.00 Mn | - |
| 5 | Iqvia Holdings | 39.29 Bn | 37.21 Bn | 1.44 Bn | - |
| 6 | Natera | 38.61 Bn | 37.51 Bn | 696.04 Mn | - |
| 7 | Illumina | 29.99 Bn | 28.82 Bn | 770.00 Mn | - |
| 8 | Mettler Toledo International | 28.57 Bn | 28.51 Bn | 650.22 Mn | - |
| 9 | Quest Diagnostics | 26.17 Bn | 25.55 Bn | 1.03 Bn | - |
| 10 | Castle Biosciences | 919.57 Mn | 652.76 Mn | 79.85 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | 1.50 Mn |
| Mar 31, 2019 | 1.50 Mn |
| Dec 31, 2018 | 27.17 Mn |
| Sep 30, 2018 | 1.50 Mn |
| Jun 30, 2018 | 1.50 Mn |